泰凌医药(01011.HK)股份续停牌以待公告草拟本之刊发
泰凌医药(01011.HK)股份於6月26日起於联交所短暂停止买卖,以待公布公司收购、合并及股份购回等内幕消息。
目前,公司已於6月26日向证监会提交公告草拟本以供其审阅及审批。公告草拟本现正由证监会审阅并正待证监会批准刊发。公司已收到由证监会就公告草拟本所提出之第一轮提问,正着手回应第一轮提问。
董事会将编制或刊发公告草拟本,以在切实可行的范围内尽快恢复股份的买卖。目前股份将继续暂停买卖以待公告草拟本之刊发。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.